Home
Conditions
Hemic and Lymphatic Diseases

Clinical trial condition

Hemic and Lymphatic Diseases

Explore clinical trials studying Hemic and Lymphatic Diseases. Study availability and eligibility vary by location and protocol.

21,074 public trials 3,988 recruiting studies

Refine in advanced search Browse all conditions

Hemic and Lymphatic Diseases trial results

Recruiting

A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors

NCT06248515

Conditions: Hemic and Lymphatic Diseases, Lymphatic Diseases, Neoplasms, +7 more
Locations: Stanford Cancer Institute Palo Alto, California, United States

Lombardi Comprehensive Cancer Center, Georgetown University Washington D.C., District of Columbia, United States

University of Chicago Medical Center Chicago, Illinois, United States

John Theurer Cancer Center at Hackensack University Medical Center Hackensack, New Jersey, United States

View Trial Details

Recruiting

Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma

NCT06830031

Conditions: DLBCL, Nos Genetic Subtypes, Dendritic Cell Sarcoma, Interdigitating, Diffuse Large B-cell-lymphoma, +22 more
Locations: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences Tianjin, China

View Trial Details

Recruiting

Systemic Therapy of Open-label Prophylactic Pravastatin or Pentoxifylline/Tocopherol Prevention of Lymphedema Advancing to Eventual Fibrosis: an Interventional Registry-embedded Bayesian Randomized Trial for Radiation Sequelae (STOP4-LATE-FIBROSE)

NCT06494111

Conditions: Fibrosis, Hemic and Lymphatic Diseases, Lymphatic Diseases, +3 more
Locations: MD Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease

NCT04744116

Conditions: Hematologic Diseases, Hematologic Neoplasms, Hematopoietic and Lymphoid Cell Neoplasm, +4 more
Locations: M D Anderson Cancer Center Houston, Texas, United States

View Trial Details

Recruiting

A Gene Therapy Study of SPK-8011QQ in Adults With Severe or Moderately Severe Hemophilia A

NCT07226206

Conditions: Blood Coagulation Disorders, Blood Coagulation Disorders, Inherited, Coagulation Protein Disorders, +6 more
Locations: Center for Inherited Blood Disorders Orange, California, United States

Kaiser Permanente Vallejo, California, United States

University of California San Francisco San Francisco, California, United States

View Trial Details

Recruiting

Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)

NCT07387926

Conditions: Acute Lymphoblastic Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +11 more
Locations: Novartis Investigative Site Ramat Gan, Israel

Novartis Investigative Site Sydney, New South Wales, Australia

Novartis Investigative Site Taipei, Taiwan

View Trial Details

Recruiting

A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant

NCT07616921

Conditions: Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Recruiting

Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia

NCT07061951

Conditions: Chronic Disease, Disease Attributes, Hematologic Diseases, +17 more
Locations: City of Hope Comprehensive Cancer Center Duarte, California, United States

City of Hope at Irvine Lennar Irvine, California, United States

University of California Davis Comprehensive Cancer Center Sacramento, California, United States

Dana-Farber Cancer Institute Boston, Massachusetts, United States

View Trial Details

Recruiting

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

NCT05006716

Conditions: B-cell Malignancy, Blood Protein Disorders, Cardiovascular Diseases, +37 more
Locations: University of Alabama At Birmingham Hospital Birmingham, Alabama, United States

Mayo Clinic Phoenix Phoenix, Arizona, United States

Honor Health Research Institute Scottsdale, Arizona, United States

University of Arizona Cancer Center Tucson, Arizona, United States

View all 115 locations

View Trial Details

Recruiting

CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia

NCT07328503

Conditions: Acute Lymphoblastic Leukemia, B-ALL, Hematologic Diseases, +10 more
Locations: National Institutes of Health Clinical Center Bethesda, Maryland, United States

View Trial Details

Hemic and Lymphatic Diseases

Hemic and Lymphatic Diseases trial results

Related conditions